Síndrome hepatorrenal
estado atual
Palavras-chave:
Síndrome hepatorrenal, Insuficiência renal, Cirrose hepática, Hipertensão portal, Agentes vasopressoresResumo
A síndrome hepatorrenal (SHR) é o desenvolvimento do quadro de insufi ciência renal em pacientes com doença hepática crônica prévia sem evidências clínica ou laboratorial de nefropatia prévia. Atinge até 18% dos pacientes cirróticos com ascite em um ano, chegando a 39% em cinco anos, com uma sobrevida média em torno de duas semanas após estabelecido o quadro. O diagnóstico da SHR baseia-se em critérios clínicos e laboratoriais. Seu aparecimento está relacionado ao mecanismo de formação de ascite, que envolve vasoconstrição e hipofl uxo renal, retenção de água e sódio, aumento do volume plasmático, e conseqüentemente hiperfl uxo no território esplâncnico. Mediadores vasoativos renais e humorais, como a endotelina 1, tromboxano A2 e leucotrienos, estão ainda envolvidos na gênese desta síndrome que culmina com insufi ciência renal funcional. O tratamento preconizado da SHR pode ser farmacológico ou cirúrgico, sendo o transplante de fígado o único efetivo e permanente, com sobrevida de até 60% em quatro anos. Após melhora da função hepática, geralmente há a reversão da insufi ciência renal. O diagnóstico precoce e a rápida terapêutica podem ampliar a expectativa de vida destes hepatopatas enquanto se aguarda o transplante hepático para seu tratamento definitivo.
Downloads
Referências
Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin Liver Dis. 2005;9(4):715-32, viii.
Gildea TR, Cook WC, Nelson DR, et al. Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU. Chest. 2004;126(5):1598-603.
Gattoni A, Marotta F, Vangieri B, Pisani G, Cristiano F. Hepa- torenal syndrome. Clin Ter. 2004;155(9):375-89.
Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):164-76.
Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229-36.
Frerichs T. Tratado práctico de las enfermedades del hígado, de los vasos hepáticos y de las vías biliares. 3rd ed. Madrid: Cárlos Billy-Bailliere; 1877.
Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet. 1956;271(6953):1121-5.
Koppel MH, Coburn JM, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the func- tionalnature of renal failure in advanced liver disease. N Engl J Med. 1969;280(25):1367-71.
Iwatsuki S, Popovtzer MM, Corman JL, et al. Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Eng J Med. 1973;289(22):1155-9.
Schroeder ET, Shear L, Sancetta SM, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med. 1967;43(6):887-96.
Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda GJ. Plasma renin level in hepatic cirrhosis. Relaton to functional renal failure. Am J Med. 1970;49(2):186-91.
Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49(2):175-85.
Ring-Larsen H, Hesse B, Henriksen JH, Christensen NJ. Sym- pathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology. 1982;2(3):304-10.
Arroyo V, Planas R, Gaya J, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest. 1983;13(3):271-8.
Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 1979;77(2):215-22.
Suzuki H, Stanley AJ. Current management and novel thera- peutic strategies for refractory ascites and hepatorenal syndrome. QJM. 2001;94(6):293-300.
Gentilini P, Vizzuti F, Gentilini A, La Villa G. Ascites and hepatorenal syndrome. Eur J Gastroenterol Hepatol. 2001; 13(4):313-6.
Dagher L, Moore K. The hepatorenal syndrome. Gut. 2001; 49(5):729-37.
Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology. 1980;78(5 Pt 1):1059-68 .
Levy M, Wexler MJ. Renal sodium retention and ascites for- mation in dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity. J Lab Clin Med. 1978;91(3):520-36.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151-7.
Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993;18(5):1139-43.
Pak JM, Lee SS. Glucagon in portal hypertension. J Hepatol. 1994;20(6):825-32.
Guarner F, Guarner C, Prieto J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology. 1986;90(3):687-94.
Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol. 1995;22(3):370-6.
Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and pe- ripheral venous blood in patients with cirrhosis. Hepatology. 1988;8(2):232-6.
Lee SS, Chilton EL, Pak JM. Adenosine receptor blockade reduces splanchnic hyperemia in cirrhotic rats. Hepatology. 1992;15(6):1107-11.
Gaudin C, Braillon A, Poo JL, Moreau R, Hadengue A, Lebrec
D. Regional sympathetic activity, severity of liver disease and hemodynamics in patients with cirrhosis. J Hepatol. 1991;13(2):161-8.
Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis. 1994;14(1):35-43.
Schrier RW, Neiederberger M, Weigert A, Gines P. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semin Liver Dis. 1994;14(1):14-22.
Gentilini P. Hepatorenal syndrome and ascites--an introduction. Liver. 1999;19(1 Suppl):5-14.
Zipser RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Uri- nary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology. 1983;84(4):697-703.
Huber M, Kastner S, Scholmerich J, Gerok W, Keppler D. Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syn- drome. Eur J Clin Invest. 1989;19(1):53-60.
Morrow JD, Moore KP, Awad JA, et al. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J Lipid Mediat. 1993;6(1-3):417-20.
Moore K. The hepatorenal syndrome. Clin Sci (Lond). 1997;92(5):433-43.
Mullane JF, Gliedman ML. Elevation of the pressure of the ab- dominal inferior vena cava as a cause of a hepatorenal syndrome in cirrhosis. Surgery. 1966;59(6):1135-46.
Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495-501.
Dudley FJ, Kanel GC, Wood LJ, Reynolds TB. Hepatorenal syndrome without avid sodium retention. Hepatology. 1986;6(2):248-51.
Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klint- malm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. Transplantation. 1991;51(2):428-30.
Roberts LR, Kamath PS. Ascites and hepatorenal syn- drome: pathophysiology and management. Mayo Clin Proc. 1996;71(9):874-81.
Gines A, Fernandez-Esparrach G, Monescillo A, et al. Random- ized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastro- enterology. 1996;111(4):1002-10.
Bennett WM, Keeffe E, Melnyk C, Mahler D, Rosch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med. 1975;135(7):964-71.
Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30(4):870-5.
Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol. 1998;29(4):565-70.
Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33(1):43-8.
Kalambokis G, Milionis H, Elisaf M, Tsianos EV. Terlipressin avoids hemodialysis in the treatment of refractory hyperkale- mia associated with renal dysfunction in cirrhosis. Am J Med. 2005;118(9):1051-2.
Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepa- torenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690-7.
Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28(4):937-43.
Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Ver- berckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol. 1990;11(2):153-8.
Gines A, Salmeron JM, Gines P, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol. 1993;17(2):220-6.
Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet. 1996;347(9018):1842-3.
Holt S, Goodier D, Marley R, et al. Improvement of renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999;353(9149):294-5.
Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non- transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47(2):288-95.
Barshes NR, Gay AN, Williams B, Patel AJ, Awad SS. Support for the acutely failing liver: a comprehensive review of historic and contemporary strategies. J Am Coll Surg. 2005;201(3):458-76.
Mitzner SR, Stange J, Klammt S, et al. Improvement of hepa- torenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6(3):277-86.
Solis-Herruzo JA, Duran A, Favela V, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol. 1987;5(2):167-73.
Atallah AN, Trevisani VFM, Valente O. Princípios para tomadas de decisões terapêuticas com base em evidências científicas. In: Borges DR, Rothschild HA, editors. Atualização Terapêutica. 21a ed. São Paulo: Artes Medicas; 2003. p. 1704-6.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
